Metraipolis › archive › dc_b2ac8e298dba

Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer — Europe PMC PMID:41063984

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41063984
DOI
10.3389/fimmu.2025.1658740
License (as archived)
solo-consultazione
Archived
2026-11-09T19:34:39.878Z
SHA-256 of the archived text
28646b9b31a71f1b4a123925abdd550c40d47bc5d30007b49709d6c0f0ba2a0d
Stable URL of this page
https://metraipolis.com/documento/dc_b2ac8e298dba

How to cite

Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer — Europe PMC PMID:41063984 — Europe PMC (en), https://europepmc.org/article/MED/41063984 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b2ac8e298dba (Metraipolis archive dc_b2ac8e298dba, sha256 28646b9b31a71f1b4a123925abdd550c40d47bc5d30007b49709d6c0f0ba2a0d)
BibTeX
@misc{dcb2ac8e298dba,
  title = {Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer — Europe PMC PMID:41063984},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41063984},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b2ac8e298dba; sha256 28646b9b31a71f1b4a123925abdd550c40d47bc5d30007b49709d6c0f0ba2a0d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41063984. Agents can read the archived copy with the MCP tool read_document.